Gene transfers of vascular endothelial growth factor-a, vascular endothelial growth factor-b, vascular endothelial growth factor-c, and vascular endothelial growth factor-D have no effects on atherosclerosis in hypercholesterolemic low-density lipoprotein-receptor/apolipoprotein B48-deficient mice

被引:76
作者
Leppänen, P
Koota, S
Kholová, I
Koponen, J
Fieber, C
Eriksson, U
Alitalo, K
Ylä-Herttuala, S
机构
[1] Univ Kuopio, AI Virtanen Inst, Dept Mol Med, FIN-70211 Kuopio, Finland
[2] Kuopio Univ Hosp, Dept Med, SF-70210 Kuopio, Finland
[3] Kuopio Univ Hosp, Gene Therapy Unit, SF-70210 Kuopio, Finland
[4] Ludwig Inst Canc Res, S-10401 Stockholm, Sweden
[5] Univ Helsinki, Biomedicum, Canc Biol Lab, FIN-00014 Helsinki, Finland
关键词
genes; atherosclerosis; gene transfer;
D O I
10.1161/CIRCULATIONAHA.105.534107
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background - The role of vascular endothelial growth factors ( VEGFs) in large arteries has been proposed to be either vasculoprotective or proatherogenic. Because VEGF family members are used for human therapy, it is important to know whether they could enhance atherogenesis. We tested the effects of the members of the VEGF gene family on atherogenesis in LDL- receptor/ apolipoprotein ( apo) B48 double- knockout ( LDLR/ apoB48) mice using systemic adenoviral gene transfer. Methods and Results - Six groups of LDLR/ apoB48- deficient mice ( n = 110) were kept 3 months on a Western- type diet. After 6 weeks of diet, mice were injected via tail vein with recombinant adenoviruses expressing VEGF- A, - B, - C, or - D or LacZ ( 1 x 10(9) PFU) or rhVEGF- A protein ( 2 mu g/ kg) and euthanized 6 weeks later. Also, older mice ( n = 36) were injected after 4 months on the diet and euthanized 6 weeks later ( total time on the diet, 22 weeks) to evaluate the effects of gene transfers on the development of more mature lesions. Aortas were analyzed for the presence of macroscopic lesions, cross- sectional lesion areas, neovascularization, and cellular composition of the lesions. All groups had equivalent plasma cholesterol and triglyceride levels. Gene transfers with recombinant adenoviruses or administration of rhVEGF- A protein had no statistically significant effects on en face atherosclerotic lesions in the aorta, cross- sectional lesion area, neovascularization, or cellular composition of the lesions. Conclusions - This study shows no proatherogenic effects of adenovirus- mediated gene transfers of VEGF- A, - B, - C, or - D in the LDLR/ apoB48- deficient hypercholesterolemic mice, in which lipoprotein profile and atherosclerosis closely resemble those in human disease.
引用
收藏
页码:1347 / 1352
页数:6
相关论文
共 26 条
[1]
Aase K, 1999, DEV DYNAM, V215, P12, DOI 10.1002/(SICI)1097-0177(199905)215:1<12::AID-DVDY3>3.3.CO
[2]
2-E
[3]
Vascular endothelial growth factor enhances atherosclerotic plaque progression [J].
Celletti, FL ;
Waugh, JM ;
Amabile, PG ;
Brendolan, A ;
Hilfiker, PR ;
Dake, MD .
NATURE MEDICINE, 2001, 7 (04) :425-429
[4]
Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice [J].
Fazio, S ;
Babaev, VR ;
Burleigh, ME ;
Major, AS ;
Hasty, AH ;
Linton, MF .
JOURNAL OF LIPID RESEARCH, 2002, 43 (10) :1602-1609
[5]
Molecular and biological properties of vascular endothelial growth factor [J].
Ferrara, N .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1999, 77 (07) :527-543
[6]
Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia -: Phase II results of the Kuopio Angiogenesis Trial (KAT) [J].
Hedman, M ;
Hartikainen, J ;
Syvänne, M ;
Stjernvall, J ;
Hedman, A ;
Kivelä, A ;
Vanninen, E ;
Mussalo, H ;
Kauppila, E ;
Simula, S ;
Närvänen, O ;
Rantala, A ;
Peuhkurinen, K ;
Nieminen, MS ;
Laakso, M ;
Ylä-Herttuala, S .
CIRCULATION, 2003, 107 (21) :2677-2683
[7]
Vascular endothelial growth factor in ischemia for vascular angiogenesis [J].
Henry, TD ;
Annex, BH ;
McKendall, GR ;
Azrin, MA ;
Lopez, JJ ;
Giordano, FJ ;
Shah, PK ;
Willerson, JT ;
Benza, RL ;
Berman, DS ;
Gibson, CM ;
Bajamonde, A ;
Rundle, AC ;
Fine, J ;
McCluskey, ER .
CIRCULATION, 2003, 107 (10) :1359-1365
[8]
Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions - Possible pathophysiological significance of VEGF in progression of atherosclerosis [J].
Inoue, M ;
Itoh, H ;
Ueda, M ;
Naruko, T ;
Kojima, A ;
Komatsu, R ;
Doi, K ;
Ogawa, Y ;
Tamura, N ;
Takaya, K ;
Igaki, T ;
Yamashita, J ;
Chun, TH ;
Masatsugu, K ;
Becker, AE ;
Nakao, K .
CIRCULATION, 1998, 98 (20) :2108-2116
[9]
Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knock-out mice [J].
Jalkanen, J ;
Leppänen, P ;
Närvänen, O ;
Greaves, DR ;
Ylä-Herttuala, S .
ATHEROSCLEROSIS, 2003, 169 (01) :95-103
[10]
Direct intramyocardial plasmid vascular endothelial growth factor-A165-gene therapy in patients with stable severe angina pectoris -: A randomized double-blind placebo-controlled study:: The Euroinject One trial [J].
Kastrup, J ;
Jorgensen, E ;
Rück, A ;
Tägil, K ;
Glogar, D ;
Ruzyllo, W ;
Botker, HE ;
Dudek, D ;
Drvota, V ;
Hesse, B ;
Thuesen, L ;
Blomberg, P ;
Gyöngyösi, M ;
Sylvén, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (07) :982-988